19 May 2022 | News
John will provide guidance to the senior management at HistoIndex
Singapore's HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, is very pleased to announce the appointment of Dr. David John Jeans CBE as Non-Executive Director of the company's Board. John brings with him a global and diverse experience in life sciences, along with a deep interest in healthcare technologies to improve clinical standards and care for patients. His vast professional background spans more than 45 years in medical devices, pharmaceutical development, in-vivo and in-vitro diagnostics encompassing research, product development, manufacturing, and commercialisation.
John will provide guidance to the senior management at HistoIndex to transform histopathological standards in diagnostics and drug development with the global adoption of stain-free AI digital pathology for fibrotic diseases.
John has helmed senior leadership positions in international healthcare corporations such as Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc, which is now GE Healthcare. He was previously the Chairman of Cardiff University, Deputy Chief Executive of the Medical Research Council, chaired the Trustee Board of MRC Technology, involved in the Science Advisory Council for Wales, and served as Trustee of the Francis Crick Institute. He is currently the Chairman of the Digital Health & Care Innovation Centre in Scotland and notably in Singapore, John is a co-Chair of the Strategic Advisory Panel at the Diagnostics Development Hub (DxD Hub), led by the Agency for Science, Technology and Research (A*STAR).